close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Athira Pharma, Inc.

< Previous 1 2 Next >
News headline image
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Participate in Jefferies London Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Participate in Upcoming October Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Participate in Upcoming June Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Participate in Upcoming May Investor Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Provides 2023 Pipeline Outlook
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
News headline image
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Tickers ATHA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today